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Background: Comorbidity has an adverse impact on cancer survival partly through its negative impact on receipt
of curative treatment. Comorbidity is unevenly distributed within populations, with some ethnic and socioeconomic
groups having considerably higher burden. The aim of this study was to investigate the inter-relationships between
comorbidity, ethnicity, receipt of treatment, and cancer survival among patients with stomach and liver cancer in
New Zealand.
Methods: Using the New Zealand Cancer Registry, Māori patients diagnosed with stomach and liver cancers were
identified (n = 269), and compared with a randomly selected group of non-Māori patients (n = 255). Clinical and
outcome data were collected from medical records, and the administrative hospitalisation and mortality databases.
Logistic and Cox regression modelling with multivariable adjustment were used to examine the impacts of ethnicity
and comorbidity on receipt of treatment, and the impact of these variables on all-cause and cancer specific survival.
Results: More than 70% of patients had died by two years post-diagnosis. As comorbidity burden increased among
those with Stage I-III disease, the likelihood that the patient would receive curative surgery decreased (e.g. C3 Index
score 6 vs 0, adjusted OR: 0.32, 95% CI 0.13-0.78) and risk of mortality increased (e.g. C3 Index score 6 vs 0, adjusted
all-cause HR: 1.44, 95% CI 0.93-2.23). Receipt of curative surgery reduced this excess mortality, in some cases
substantially; but the extent to which this occurred varied by level of comorbidity. Māori patients had somewhat
higher levels of comorbidity (34% in highest comorbidity category compared with 23% for non-Māori) and
poorer survival that was not explained by age, sex, site, stage, comorbidity or receipt of curative surgery (adjusted
cancer-specific HR: 1.36, 95% CI 0.97-1.90; adjusted all-cause HR: 1.33, 95% CI 0.97-1.82). Access to healthcare
factors accounted for 25-36% of this survival difference.
Conclusions: Patients with comorbidity were substantially less likely to receive curative surgery and more likely
to die than those without comorbidity. Receipt of curative surgery markedly reduced their excess mortality.
Despite no discernible difference in likelihood of curative treatment receipt, Māori remained more likely to die
than non-Māori even after adjusting for confounding and mediating variables.
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Patients with cancer often carry the dual burden of the can-
cer itself and other co-existing chronic conditions. Comor-
bidity can have a substantial impact on the patient, their
clinicians and the health services in general [1-5]. The role
of comorbidity in the care and outcomes of cancer patients
is complex with the inter-relationships between comorbid-
ity, receipt of treatment and outcomes for cancers poorly
understood. The impact of these factors in explaining
disparities in cancer survival between patients in different
ethnic or socioeconomic groups remains even less clear.
Comorbidity is known to have a negative impact on
the likelihood of receiving curative treatment among
cancer patients generally [6-14]. For example, a system-
atic review of studies analysing the use of chemotherapy
among stage III colon cancer patients in the US reported
that seven out of nine studies found comorbidity had
a deleterious effect on chemotherapy receipt [15]. The
magnitude of the effect was large with the odds ratios
comparing the uptake of chemotherapy among patients
with Charlson (global measure of comorbidity) scores
of 2 or 3+ with those with scores of 0 ranging from
0.38-0.44 in one large study [15]. The impact of comor-
bidity on treatment for stomach and liver cancers
specifically has not been established.
This issue is important because whilst it is clear that
those with comorbidity have poorer cancer survival, it is
not entirely clear the extent to which this occurs due to the
direct effect of comorbidity or through its impact on treat-
ment choice or effectiveness. Intuitively it is likely that both
play a part. Few studies have investigated this issue, but
those that do suggest that, among cancer patients, at least
part of the excess mortality among those with comorbidity
is due to lower receipt of definitive treatment [13,14].
Comorbidity is common among cancer patients in gen-
eral, but those in ethnic minority and lower socioeco-
nomic groups frequently carry a greater burden of chronic
disease than others [16-19]. These same groups often
experience poorer cancer survival [19-22]. Comorbidity
has been shown to be in part responsible for these dispar-
ities in cancer survival. For example, a study by Hill et al.
[20] showed that a third of the disparity in colon cancer
survival between Māori (Indigenous New Zealanders)
and non-Māori New Zealanders was due to comorbid-
ity. Studies in other countries have similarly found that
disparities in cancer survival between indigenous and
non-indigenous populations are, at least partially, ex-
plained by differences in levels of comorbidity [19,23].
In the US, the evidence relating to the impact of comor-
bidities on ethnic/racial inequalities in outcomes is in-
consistent. Several authors have found that comorbidity
partially or completely explains such disparities [14,24-29],
while others have concluded that comorbidity may not be
important in this regard [30-32].This study aims to investigate the inter-relationships
between comorbidity, receipt of treatment, ethnicity and
cancer survival among a cohort of patients with liver
and stomach cancers in New Zealand. Internationally,
stomach and liver cancers are the third- and fourth lead-
ing causes of cancer deaths respectively [33].
The specific objectives of this study are to investigate:
1) the impact of comorbidity on receipt of curative treat-
ment; 2) the impact of comorbidity on all-cause and
cancer-specific survival, and the proportion of any excess
mortality explained by lack of receipt of treatment and
3) the extent to which comorbidity and receipt of
definitive treatment explains differences in survival be-




Incident cases of stomach (ICD-10-AM code: C16.×)
and hepatocellular (C22.0) cancers diagnosed between 1
Jan 2006 and 31 Dec 2008 were identified from the New
Zealand Cancer Registry (NZCR). These cancers were
combined because there were insufficient numbers of
either alone for this study, and there are similarities
between these cancers in that both are associated with
chronic infection, smoking and alcohol consumption, so
are similarly related to comorbidity; both are treated by
upper gastrointestinal surgeons and have surgery as their
primary treatment modality, and both are associated
with similarly poor survival.
New Zealand has mandatory reporting of all cancers
(except non-melanoma skin cancer). Patients were eli-
gible for inclusion if they a) were aged 25 years or older
at diagnosis; b) were normally resident in New Zealand;
c) had no previous diagnosis of the same primary cancer;
and d) were diagnosed prior to their death. New Zealand
is divided into two main Islands (North and South), with
nearly 80% of the population (and specifically 90% of the
Māori population) based in the North Island [34]. All
eligible Māori patients (who make up 15% of the total
population) residing in the North Island were included,
along with an equal number of randomly-sampled non-
Māori patients. The purpose of this was to ensure that
the study had equal explanatory power for Māori and
non-Maori. Ethnicity was classified on the basis of
Cancer Registry data which uses an ever-Māori approach,
where patients are classified as Māori if they have been
identified as Māori on any previous health record. All
other patients were classified as non-Māori.
Clinical data relating to each patient were extracted
from all relevant public and private hospitals in the
North Island by a trained oncology nurse. Data were
recorded on a standardised study pro-forma, double-
entered and any discrepancies resolved. Details of this
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lected from routine administrative hospital records (Na-
tional Minimum Dataset) for the five years prior to
diagnosis (for assessment of comorbidity), and the na-
tional mortality collection up to the end of 2010 (provid-
ing a minimum of two years of follow-up data for all
patients). Approval for this study was granted by the
New Zealand Multi-Region Ethics Committee (MEC/10/
042/EXP), and permission for access to the data given
by the Ministry of Health and relevant District Health
Boards.
Variables
Sex, age at diagnosis, and prioritised ethnicity (Māori or
non-Māori) were determined from the Cancer Registry.
Socioeconomic deprivation and urban/rural classification
were determined using the domicile of residence data re-
corded on the Cancer Registry at time of diagnosis.
Deprivation was measured using the NZDep index, a
small-area based index calculated using aggregated cen-
sus data based on residents’ socioeconomic characteris-
tics (such as benefit receipt, earning under an income
threshold, housing tenure, access to car or phone, etc.)
[36]. Higher values of the NZDep index indicate greater
deprivation.
The clinical notes review provided data on details of
patient’s presentation (including a specified list of co-
morbid conditions present at the time of diagnosis),
tumour characteristics (including tumour grade, and
stage at diagnosis, classified according to the TNM clas-
sification system [37]), and receipt of treatment (includ-
ing surgery, chemotherapy, radiotherapy and palliative
care). Curative surgery was defined as surgical interven-
tion among those with Stage I-III disease for whom the
treatment intent was curative.
Comorbidity was measured in two ways. First, the 12
most common comorbid conditions identified in the
notes review were included in the analysis. Conditions
were treated individually, or as a categorised ‘count’ to
assess the overall burden of comorbidity at diagnosis.
Second (and separately), all conditions recorded in the
administrative hospitalisation data in the five years prior
to diagnosis were identified and used to calculate a C3
comorbidity index score for each patient [38]. The C3
index is a cancer-specific index of comorbidity based on
the presence of 42 chronic conditions each of which is
weighted to its impact on one-year non-cancer mortality
in a cancer cohort [39]. These weights are then summed
to arrive at a final comorbidity (C3 Index) score. For de-
scriptive analysis of the study cohort, C3 Index scores
were categorised into ‘0’ (C3 Index score < =0), ‘1’ (0 <
score < =1), ‘2’ (1 < score < =2) and ‘3’ (score >2) Comor-
bid conditions that may have been complications of the
primary disease or its treatment were only included ifthey were recorded prior to the date of diagnosis or
index date of admission (specifically myocardial infarc-
tion, congestive heart failure, pulmonary embolism, anx-
iety/behavioural disorders, anaemias, hypertension and
cardiac arrhythmias). In addition, conditions that may
have been indicative of early malignancy were excluded;
specifically liver disease and upper gastrointestinal
‘comorbidity’ were excluded when calculating the C3
index score for patients with liver and stomach can-
cers, respectively.
Statistical analysis
Māori, non-Māori and total cohorts were compared for
demographic and disease characteristics, patient comor-
bidity and receipt of definitive treatment. Because all
Māori patients were included but only a subset of non-
Māori patients, the estimates reported for the total
cohort were weighted to the total eligible Māori and
non-Māori stomach and liver cancer populations. When
reporting estimates stratified by ethnicity, rates were
age-standardised to the total New Zealand cancer popu-
lation (2006–2008) using direct standardisation. These
analyses were repeated restricted to those with stage
I-III disease only. To assess the association between
ethnicity and comorbidity, we fitted a linear regression
model with the C3 score as the continuous outcome, in
order to estimate a mean difference in C3 score adjust-
ing for age as a continuous predictor using restricted
cubic splines (see next paragraph). We assessed two-year
all-cause and cancer-specific survival using a Kaplan-Meier
approach.
Next, a series of multivariable models were fitted to
explore the relationships between comorbidity, ethnicity,
treatment and survival. In these models age was treated
as a continuous variable, and modelled using restricted
cubic splines with knots at the 5th, 50th, and 95th percen-
tiles. Comorbidity was treated in two ways in these
models. When comorbidity was the primary independ-
ent variable the C3 index score was used, treated as a
continuous variable and included using restricted cubic
splines with knots at the 5th, 50th, and 95th percentiles
[40]. When comorbidity was being treated as a con-
founding or mediating variable, the C3 index was in-
cluded in models (using splines as described above),
alongside a continuous comorbidity count from the hos-
pital notes review data.
To assess the extent to which comorbidity and ethni-
city impacted on the receipt of definitive treatment, pa-
tients with Stage IV cancer were excluded from the
analysis (since treatment for these patients is indicated
for palliative purposes only). First, a logistic regression
model was fitted examining the impact of comorbidity
on receipt of definitive treatment. Age (modelled as con-
tinuous, with restricted cubic splines), sex (M/F), site
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ear predictor, in deciles), rurality (rural/non-rural) and
ethnicity (Māori/non-Māori) were all treated as potential
confounders because they are common causes of both
comorbidity and receipt of treatment (see Additional file
1: Figure S1 for causal diagrams). Stage (categorised I, II,
III) was fitted last because comorbidity may impact stage
at diagnosis (although the direction and magnitude of
this impact is unpredictable) [41,42], and stage in turn
has an impact on whether or not definitive treatment
can be offered and so could be considered both a con-
founder and a mediator in this relationship.
Next, we assessed the impact of receipt of definitive
treatment on all-cause and cancer-specific survival using
Cox proportional hazards regression. For these analyses,
age, sex, site, stage, ethnicity, deprivation, rurality and
comorbidity (using both measures) were all considered
confounders and included in the model (See Additional
file 1: Figure S1 for causal diagrams).
We then assessed the impact of comorbidity (C3
Index scores) on survival, and the extent to which this
was mediated by receipt of definitive treatment. For
these analyses, age, sex, site, ethnicity, deprivation and
rurality were considered confounders. Stage of disease
was fitted next (for aforementioned reasons), followed
by receipt of definitive treatment.
To assess whether ethnicity had an impact on receipt
of definitive treatment, and the extent to which this
association was mediated by comorbidity, a logistic re-
gression model was fitted. For these models, age, sex
and site were considered confounders and were added
to the model first, followed by stage. Stage was consid-
ered a mediator because ethnicity is likely to impact on
stage of diagnosis through factors such as uneven access
to primary care services, which in turn impacts on treat-
ment. We were interested in the impact of comorbidity
once the effect of stage at diagnosis had been accounted
for. Comorbidity was added to the model (using both
the C3 index score and the count of the number of
comorbidities) to estimate the extent to which the poten-
tial remaining effect of ethnicity on receipt of treatment
was caused by differential levels of comorbidity between
ethnic groups. Access to healthcare factors (deprivation
and rurality) were added last as additional potential medi-
ators in this association.
Finally, to assess the impact of ethnicity and comor-
bidity on (all-cause and cancer-specific) survival, Cox
regression models were fitted following the same se-
quential model adjustment protocol as outlined above
(with the addition of receipt of curative treatment). For
all Cox regression models, individuals were censored at
the end of follow up time. For cancer-specific analyses,
patients were censored at their date of death if they
died of non-cancer causes.All analyses were carried out in SAS v9.2. Those models
with exposures fit with restricted cubic spline variables
were conducted using an add-in macro [40] which also
produces solutions of the odds/hazard ratios at specified
points in the exposure distribution.
Results
There were 269 Māori patients and 255 non-Māori pa-
tients (total n = 524) included in this study. Patient char-
acteristics are shown in Table 1. Patients with stomach
cancer comprised 64% of the total cohort. Males formed
the majority of the cohort (67% versus 33% female). The
overall mean age was 64 years (SD = 15), with the Māori
cohort having a younger mean age (Māori: 60 years, SD
14; Non-Māori: 68 years, SD 14; p <0.001). A substantial
proportion of the cohort was recorded as having late-
stage disease, with 43% diagnosed at Stage IV. There
were 293 patients with stage I-III disease. The profile for
stage of disease at diagnosis was similar for Māori and
non-Māori. Māori were considerably more likely to res-
ide in areas of high deprivation than non-Māori (age-
adjusted proportion residing in NZDep deciles 9–10,
Māori: 60%, non-Māori: 27%; p <0.001). Māori were also
less likely to reside in an urban area compared to non-
Māori (age-adjusted proportion residing in urban area,
Māori: 65%, non-Māori 83%; p <0.001). More than 70%
of all patients in both ethnic groups and for both stom-
ach and liver cancers had died within two years of diag-
nosis (Table 2). Additional file 1: Table S1 shows patient
characteristics for those diagnosed with Stage I to III
disease only; with the distribution of characteristics
being very similar as for the full cohort.
The distribution of the cohort by comorbidity (‘C3
Index’) category is shown in Table 1 (and Additional
file 1: Table S1), with the range being 0 to 12.8. Propor-
tionally, the greatest number of patients were recorded as
having no comorbidity (C3 Index category ‘0’; weighted
proportion of total cohort: 40%), but 28% in the total
cohort had levels of comorbidity in the highest category
(C3 index category 3). Age-standardised results sug-
gested that proportionally fewer Māori patients had no
comorbidity (age-standardised proportion: Māori 36%,
non-Māori 43% in the total cohort) and proportionally
more had a comorbidity score >2 (Māori: 34%, non-
Māori 23%). Linear regression analysis confirmed that
Māori tended to have a higher comorbidity burden than
non-Māori (age adjusted mean difference: 0.42, 95% CI
0.06-0.78). Additional file 1: Table S2 provides the other
characteristics of the cohort (site, gender, age, stage,
deprivation and rurality) by comorbidity category.
Hypertension was the most common comorbid con-
dition identified from the clinical notes review data
(weighted proportion of total cohort: 39%), with Māori
more likely to suffer this condition than non-Māori
Table 1 Characteristics of the study population: proportions by site sex, age, stage, deprivation, rurality and
comorbidity
Māori Non-Māori
Total cohort1 Unadj Age Std2 Unadj Age Std2
n (total =524) % n (total =269) % % n (total =269) % % p
Cancer site
Liver cancer 189 36% 97 36% 92 36%
Stomach cancer 335 64% 172 64% 163 64%
Sex 0.104
Male 349 67% 170 63% 64% 179 70% 70%
Female 175 33% 99 37% 36% 76 30% 30%
Age (years)
25-49 105 20% 73 27% - 32 13% -
50-64 152 29% 96 36% - 56 22% -
65-74 139 27% 64 24% - 75 29% -
75+ 128 24% 36 13% - 92 36% -
Mean age (SD) 64 (15) 60 (14) 68 (14) <0.001
Stage (TNM) 0.688
I 84 16% 41 15% 16% 43 17% 17%
II 93 18% 51 19% 19% 42 16% 17%
III 116 22% 59 22% 22% 57 22% 22%
IV 226 43% 118 44% 42% 108 42% 43%
Unstaged 5 1% 0 - - 5 2% 2%
NZDep (Deciles) <0.001
Lowest deprivation: 1-2 38 7% 12 5% 5% 26 10% 10%
3-4 61 12% 18 7% 7% 43 17% 17%
5-6 81 16% 32 12% 11% 49 20% 19%
7-8 112 22% 47 18% 18% 65 26% 27%
Highest deprivation: 9-10 217 43% 151 58% 60% 66 27% 27%
Rurality <0.001
Urban 371 73% 166 64% 65% 205 82% 83%
Independent urban 77 15% 51 20% 19% 26 10% 10%
Rural 61 12% 43 17% 16% 18 7% 7%
Common comorbidities
Angina 78 16% 36 13% 17% 42 16% 14% 0.376
Hypertension 200 39% 106 39% 46% 94 37% 33% <0.001
Myocardial infarction 41 9% 16 6% 7% 25 10% 8% 0.735
Arrhythmia 84 17% 38 14% 18% 46 18% 16% 0.545
CHF 51 9% 29 11% 15% 22 9% 7% <0.001
Mild CPD 32 6% 17 6% 7% 15 6% 5% 0.385
Mod/Severe CPD 41 9% 16 6% 8% 25 10% 8% 0.818
CVD 53 12% 19 7% 9% 34 13% 11% 0.418
Uncomplicated diabetes 131 23% 74 28% 29% 57 22% 22% 0.100
Other primary tumour 48 10% 19 7% 8% 29 11% 10% 0.595
Mod/severe renal disease 27 4% 19 7% 9% 8 3% 3% <0.001
Obesity 45 7% 31 12% 10% 14 5% 5% 0.028
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Table 1 Characteristics of the study population: proportions by site sex, age, stage, deprivation, rurality and
comorbidity (Continued)
C3 Index category3 0.050
0 212 40% 108 40% 36% 104 41% 43%
1 92 18% 47 17% 17% 45 18% 19%
2 74 14% 35 13% 13% 39 15% 15%
3 146 28% 79 29% 34% 67 26% 23%
1Total cohort results weighted to total liver/stomach cancer population (2006–2008). 2Age standardised to total NZ cancer population (2006–2008). 3 C3 index
category: ’0’ (C3 Index score < =0), ‘1’ (0 < score < =1), ‘2’ (1 < score < =2) and ‘3’ (score >2).
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33%; p <0.01). Uncomplicated diabetes (23%), arrhythmia
(17%) and angina (16%) were also common. Māori were
more likely to be reported as having congestive heart fail-
ure (age-standardised proportion: Māori: 15%, non-Māori
7%, p <0.01), moderate/severe renal disease (Māori 9%,
non-Māori: 3%; p <0.01) and obesity (Māori: 10%, non-
Māori: 5%; p =0.03) than non-Maori.
The likelihood of receiving curative treatment reduced in
a linear manner with increasing comorbidity (Table 3). For
example, those with a C3 Index score of 6 had substantially
reduced odds of receipt of curative surgery compared to a
C3 Index score of 0, even after adjusting for age, sex, site
of cancer, stage of disease, ethnicity, deprivation and rural-
ity (adjusted OR: 0.32, 95% CI 0.13-0.78).
Receipt of curative surgery was strongly associated
with mortality. Those Stage I-III patients who did not
receive surgery were three and a half times more likely
to die than those who received surgery (cancer-specific
HR =3.68, 95% CI 2.49-5.45; all-cause HR =3.54, 95% CI
2.33-5.34; both models adjusted for age, sex, site, stage,
ethnicity, deprivation, rurality and comorbidity).
There was an association between comorbidity and
cancer survival but this was non-linear among those
with stage I-III disease after adjusting for age, sex, site,Table 2 Crude all-cause and cancer-specific 2-year survival by
All-cause survival












Non-Māori 163 27%stage, ethnicity, deprivation and rurality (Table 4). For
example, while a C3 Index score of 3 was associated
with a 54-62% increased likelihood of death compared
to those with a score of 0 (adjusted HRs: cancer-specific
1.62, 95% CI 1.03-2.54; all-cause 1.54, 95% CI 1.01-2.35),
there tended to be a drop-off in risk of mortality beyond
this point (e.g. C3 index score 6 vs 0, cancer-specific
HR: 1.15, 95% CI 0.71-1.87; all-cause HR: 1.44, 95% CI
0.93-2.23).
The introduction of receipt of curative surgery into
the models substantially reduced excess mortality among
those with comorbidity; for example, the adjusted excess
mortality among those with a C3 Index score of 3 (com-
pared to 0) was reduced by almost half, once treatment
receipt was included in the model (reduction in excess
mortality: cancer-specific 45%; all-cause 48%; treatment-
adjusted HRs: cancer-specific 1.34, 95% CI 0.84-2.13;
all-cause HR 1.28, 95% CI 0.83-1.99;).
On examining ethnic differences in treatment receipt
and survival (Table 5), Māori and non-Māori patients had
similar odds of curative surgery after adjusting for age,
sex, site, stage and comorbidity (adjusted odds ratio [OR]:
non-Māori referent; Māori 1.07, 95% CI 0.57-1.99). Māori
appeared more likely to die than non-Māori after adjusting
for age, sex, site, stage of disease, comorbidity and receiptcancer site, including median survival time in months
Cancer-specific survival










Table 3 Association between comorbidity and treatment receipt among stage I-III patients: unadjusted and adjusted
odds ratios
Impact of comorbidity evaluated at C3 score of:* Unadjusted OR (95% CI) Adj OR ** (95% CI)
0 1.00 1.00
1 0.70 (0.50-0.98) 0.92 (0.59-1.42)
2 0.53 (0.31-0.89) 0.80 (0.40-1.6)
3 0.42 (0.23-0.78) 0.66 (0.29-1.49)
6 0.29 (0.15-0.56) 0.32 (0.13-0.78)
* evaluation of the OR at a score of 1, 2, 3 and 6 (in relation to a score of 0). No results are presented beyond 6 as the 95th percentile of the C3 Index score
distribution was 6.74, which means estimates of the OR beyond this point on the scale are of limited utility.
** adjusted for age (continuous), sex, site (stomach/ liver), stage (I, II, III), deprivation (continuous, in deciles), rurality (rural/other), ethnicity (Māori/ Non-Māori).
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although confidence intervals around these estimates in-
cluded the null (adjusted HRs: cancer-specific 1.36, 95%
CI 0.97-1.90; all-cause 1.33, 95% CI 0.97-1.82). Addition-
ally adjusting for access to healthcare factors (deprivation
and rurality) accounted for 25% of the remaining excess
cancer-specific and 36% of the excess all-cause mortality.
Discussion
In a cohort of patients with liver and stomach cancers,
increasing levels of comorbidity were associated with a
reducing likelihood of receipt of definitive treatment.
Receipt of definitive treatment was, in turn, strongly
associated with survival. Comorbidity was also associ-
ated with poorer cancer-specific and all-cause survival,
although the association levelled off for those with the
highest comorbidity scores. Receipt of curative surgery
substantially reduced excess mortality among those with
comorbidity, the extent of which varied non-linearly by
level of comorbidity. Māori patients were about a third
more likely to die from their cancer or all-causes, afterTable 4 Cancer-specific and all-cause survival by category of
Cancer













1Adjusted for age, sex, site, stage, ethnicity, deprivation and rurality 2 Adjusted for a
score of 1, 2, 3 and 6 (in relation to a score of 0). No results are presented beyond 6
means estimates of the OR beyond this point on the scale are of limited utility.adjusting for age, sex, site and stage of disease, but this
was largely not explained by comorbidity or receipt of
definitive treatment. Access to healthcare factors accounted
for a quarter of cancer-specific and a third of all-cause
survival difference.
The high prevalence of comorbidity among this group
of patients with stomach and liver cancers was expected
given the risk profile of these cancers which includes
smoking, alcohol and obesity as well as chronic infection
[43]. Research has clearly established that cancer pa-
tients who also have other chronic conditions are less
likely to receive definitive treatment for their cancer,
although evidence relating to liver and stomach cancers
specifically is sparse [6-14]. Vignette-based studies that
ask clinicians to consider decisions on the basis of sum-
marised information about hypothetical patients have
also consistently found that surgeons and oncologists
are less likely to refer or recommend treatment for can-
cer patients with comorbidity [44-46].
Intuitively, it is not unreasonable for clinicians (and
their patients) to be concerned about the potential forcomorbidity among those with Stage I-III disease
-specific mortality Hazard Ratios (95% CI)
ted Model 11 Model 22
1.00 1.00
1-1.71) 1.33 (1.04-1.71) 1.24 (0.96-1.6)
-2.36) 1.56 (1.05-2.31) 1.36 (0.91-2.04)
6-2.74) 1.62 (1.03-2.54) 1.34 (0.84-2.13)
8-2.61) 1.15 (0.71-1.87) 0.85 (0.51-1.4)
se mortality Hazard Ratios (95% CI)
ted Model 11 Model 22
1.00 1.00
6-1.6) 1.25 (0.99-1.58) 1.17 (0.92-1.48)
4-2.17) 1.43 (0.99-2.07) 1.27 (0.87-1.85)
3-2.56) 1.54 (1.01-2.35) 1.28 (0.83-1.99)
3-2.9) 1.44 (0.93-2.23) 1.04 (0.66-1.63)
ll previous variables plus receipt of treatment. * evaluation of the OR at a
as the 95th percentile of the C3 Index score distribution was 6.74, which
Table 5 Comparison of Māori compared with non-Māori patients (Stage I-III): receipt of definitive treatment and excess
mortality
Receipt of definitive treatment Cancer-specific All-cause
OR (95% CI) HR (95% CI) HR (95% CI)
Crude 1.26 (0.79-2.02) 1.03 (0.76-1.4) 1.01 (0.76-1.35)
+ age, sex and site 0.9 (0.51-1.61) 1.28 (0.92-1.76) 1.25 (0.92-1.70)
+ stage 0.9 (0.49-1.63) 1.33 (0.96-1.85) 1.29 (0.95-1.76)
+ comorbidity* 1.07 (0.57-1.99) 1.23 (0.88-1.72) 1.23 (0.89-1.69)
+ treatment receipt - 1.36 (0.97-1.90) 1.33 (0.97-1.82)
+ health service access factors** 1.12 (0.54-2.35) 1.27 (0.88-1.85) 1.21 (0.85-1.72)
*Adjusted for both comorbidity count and C3 index.
**Adjusted for deprivation (NZDep decile) and rurality.
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treatment among those with comorbidity. However, the
evidence among cancer patients relating to the risk of
complications from treatment among those with co-
morbidity is conflicting. While some studies suggest
that those with comorbidity are at greater risk of com-
plications [11,47,48], others have reported that there is
no or minimal difference in rates of complications
between those with and without comorbidity [49-55].
This suggests that the large differences in treatment
offer and receipt between these groups with and with-
out comorbidity may not always be justifiable from the
point of view of treatment toxicity and complications.
Furthermore, as demonstrated by this and other studies,
those with comorbidity who receive definitive treatment
appear to have improved chance of survival [13,49,56].
However, the question of the extent to which treatment
(or lack thereof ) impacts on survival for those with
comorbidity ideally requires randomised controlled trial
evidence. Such trials frequently exclude older patients
and those with comorbidity are, such that the evidence
produced relates to interventions that apply to younger,
healthier patients [57-61]. Given the prevalence of
comorbidity among cancer patients, it would seem this
well-recognised issue needs to be addressed.
Our finding that Māori patients had poorer survival
than non-Māori patients is consistent with research relat-
ing to other cancers [20,62-65]. Māori patients differed
from non-Māori patients in a number of respects; they
were younger at diagnosis (mean age 60 vs. 68 years), had
somewhat higher levels of comorbidity (34% vs 23% in
highest category) and were substantially more likely to live
in more deprived (60% vs 27%) and rural areas (16% vs
7%). However, contrary to our expectations, there were no
differences between Māori and non-Māori patients in
terms of stage at diagnosis or receipt of curative surgery.
Comorbidity and treatment receipt were not able to
explain the one-third survival difference between Māori
and non-Māori patients, although access to health care
factors (deprivation and rurality) accounted for some ofthis disparity. It may be that these variables reflect some
aspects of the timeliness or quality of treatment received
that was more subtle than could be assessed in this study.
There are some potential limitations of our study.
First, it was an observational study, and the decision to
offer treatment is likely to be related to a range of vari-
ables for which we did not have information – including
both patient factors (such as social support) and disease
factors (such as tumour size). As such, the receipt (or non-
receipt) of curative surgery is almost certainly a proxy
marker for other prognostic indicators. Since these other
unmeasured variables may also be related to comorbidity,
the observed reduction in excess mortality among those
with high comorbidity following the addition of curative
surgery receipt to our survival models may be an overesti-
mate. Put another way, those who are selected to receive
surgery, even after adjusting for comorbidity, may be those
who have a better prognosis and/or are healthier than
those who are not selected for surgery. Furthermore, any
global measure of comorbidity is, by necessity, a simplifica-
tion of reality. We were unable to assess whether there
were certain comorbid conditions that were more import-
ant than others in terms of receipt of treatment or poor
outcomes due to the sample size. Because nearly half the
patients in this study had stage IV disease at diagnosis, and
because both stomach and liver cancers tend to have poor
prognosis for all groups of patients, our ability to discrim-
inate between groups of patients may have been limited.
This means there was a lack of precision around some of
our estimates and resulting wide confidence intervals.
This study has several significant strengths; first, we
were able to secure complete TNM staging data for 99%
of our cohort. Second, we collected data on the total
eligible Māori stomach and liver cancer population (and
an equal-number of randomly-selected non-Māori), mean-
ing that we had equal explanatory power for both Māori
and non-Māori patients. Third, we used two measures
of comorbidity; one based on data from clinical notes
and the other specifically designed and validated for use
among cancer populations (liver and stomach cancers
Sarfati et al. BMC Cancer 2014, 14:821 Page 9 of 11
http://www.biomedcentral.com/1471-2407/14/821included) [38]. This approach is likely to have reduced the
mismeasurement of the complex construct of patient co-
morbidity compared with other more general approaches.
Conclusions
We observed that patients with high comorbidity were
a) substantially less likely to receive curative surgery and
b) more likely to die than those without comorbidity.
Accounting for provision of curative treatment to those
with high comorbidity significantly reduced this excess
mortality. There was some evidence of an increased
comorbidity burden among indigenous Māori patients,
but no evidence of an inequality in receipt of curative
surgery. Despite adjusting for age, gender, stage of dis-
ease, comorbidity and receipt of curative surgery, indi-
genous Māori patients were still one-third more likely to
die of cancer-specific or all-causes than non-Māori.
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